Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT06851494

Safety and Efficacy of Linnea Safe PMMA 30% Use for Gluteal Augmentation.

Sponsor: LEBON PRODUTOS QUIMICOS E FARMACEUTICOS LTDA.

View on ClinicalTrials.gov

Summary

This pre-market, interventional, single-arm study aims to evaluate the safety and efficacy of LinneaSafe 30% polymethylmethacrylate (PMMA) for gluteal augmentation. The study will include 119 patients, with a total recruitment of 137 to account for a 15% drop-out rate. Eligible participants are men and women over 18 years old who express interest and are deemed suitable for the procedure. The primary safety outcome is the incidence of adverse events, while the primary efficacy outcome is patient satisfaction.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

137

Start Date

2025-11-01

Completion Date

2026-11-01

Last Updated

2025-03-04

Healthy Volunteers

Yes

Conditions

Gluteal Augmentation

Interventions

DEVICE

PMMA

Safety and efficacy evaluation of PMMA LinneaSafe 30% use for gluteal augmentation. Linnea Safe is a water-based gel containing Polymethylmethacrylate (PMMA) in concentrations of 2%, 10% or 30%. LInnea Safe is indicated for facial and body volumetric correction in cases of lipodystrophy due to the use of antiretrovirals in HIV-positive patients. It is also indicated for facial volumetric correction, and can be used in nasolabial folds, glabellar lines, corners of the mouth, upper lip lines, chin lines/chin lines, in the malar region, in acne scars, on the nose, to increase lips and facial contour.

Inclusion Criteria: * Men and women; * Older than 18 years; * Signed Informed Consent Form; Exclusion Criteria: * Prior intramuscular filling with PMMA for volumization of the buttocks or other body areas (reported by the patient or verified on ultrasound). * Clinical history or evidence on ultrasound of intramuscular injection of liquid/industrial silicone, hydrogels (except hyaluronic acid and absorbable biostimulators performed up to 6 months before), synthol, potenay, ADE vitamins or other products in the glutes * Pregnant or breastfeeding women * Presence of silicone prosthesis for gluteal augmentation; * Levels of 25 hydroxy vitamin D \> 60 mg/mL; * Vitamin D supplementation in the 3 months prior to the procedure - even with 25 hydroxy vitamin D levels between 15 and 60 mg/mL * Altered PTH (less than 12pg/mL or greater than 65 pg/mL CRP greater than 1 mg/dL (or 10 mg/L) * Erythrocyte sedimentation value 2 times higher than normal; * Women with testosterone levels greater than 70 ng/dL * Women with estrogen levels greater than 450 pg/mL * Urea value greater than 50 mg/dL * Creatinine value greater than 1.3 mg/dL * Glomerular filtration rate less than 90 mL/min * Rheumatoid factor value greater than 79 UI/mL * Ionic calcium values greater than 5.2 mg/dL (or 1.30 mmol/L) * Total calcium value greater than 10.5 mg/dL * Iron value greater than 175 µg/dL * Ferritin value greater than 336 ng/dL * Calcitriol greater than 90.1pg/dL * Uncontrolled diabetes (fasting blood glucose \> 100mg/dL) * Antinuclear factor (ANA) \> 1:160; * Personal history of more than one episode of pain due to kidney stones (except during pregnancy) * Ratio of urinary calcium and urinary creatinine in an isolated urine sample \> 250. * Patients using medications for cancer treatment * Patients with lupus, systemic scleroderma, dermatomyositis, granulomatous diseases * Any other contraindications mentioned in the product's instructions for use, such as: history of evolving autoimmune disease, during treatment with immunosuppressants, or in any disorder or active skin infection. The use is absolutely contraindicated in cases of active herpes lesions. In cases of herpetic history, prophylactic treatment is recommended. Any inflammatory reaction from injections is also a contraindication.